Theriva Biologics (TOVX) Short term Debt (2022 - 2026)
Theriva Biologics (TOVX) posted quarterly Short term Debt of $1.2 million for Q1 2026, up 2239.22% year-over-year from $51000.0 in Q1 2025, and up 1992.98% quarter-over-quarter from $57000.0 in Q4 2025.
Theriva Biologics (TOVX) Short term Debt (2022 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Short term Debt for 5 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short term Debt rose 2239.22% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (up 2239.22% YoY), while the FY2025 annual figure was $57000.0, down 6.56% from the prior year.
- Short term Debt grew to $1.2 million in Q1 2026 per TOVX's latest filing, from $57000.0 in the prior quarter.
- Across five years, Short term Debt topped out at $8.6 million in Q3 2022 and bottomed at $51000.0 in Q1 2025.
- Historically, Short term Debt has averaged $1.4 million across 5 years, with a median of $63000.0 in 2023.
- Annual changes were most pronounced in 2023 — Short term Debt tumbled 99.25% — and 2026, when it surged 2239.22%.
- Theriva Biologics' Short term Debt stood at $57000.0 in 2022, then advanced by 10.53% to $63000.0 in 2023, then slipped by 3.17% to $61000.0 in 2024, then dropped by 6.56% to $57000.0 in 2025, then surged by 1992.98% to $1.2 million in 2026.
- Business Quant data shows TOVX's Short term Debt at $1.2 million in Q1 2026, $57000.0 in Q4 2025, and $57000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.65 Mn |
| Mar 31, 2026 | 1.19 Mn |
| Dec 31, 2025 | 57,000.00 |
| Sep 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 56,000.00 |
| Mar 31, 2025 | 51,000.00 |
| Dec 31, 2024 | 61,000.00 |
| Sep 30, 2024 | 65,000.00 |
| Jun 30, 2024 | 62,000.00 |
| Mar 31, 2024 | 62,000.00 |
| Dec 31, 2023 | 63,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Jun 30, 2023 | 4.98 Mn |
| Mar 31, 2023 | 66,000.00 |
| Dec 31, 2022 | 57,000.00 |
| Sep 30, 2022 | 8.61 Mn |
| Jun 30, 2022 | 8.46 Mn |
| Mar 31, 2022 | 68,000.00 |